Trilogy Capital Inc. Purchases 434 Shares of Eli Lilly and Company $LLY

Trilogy Capital Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,436 shares of the company’s stock after purchasing an additional 434 shares during the quarter. Trilogy Capital Inc.’s holdings in Eli Lilly and Company were worth $5,000,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Decision Investments Inc. raised its holdings in Eli Lilly and Company by 2.5% in the first quarter. Decision Investments Inc. now owns 959 shares of the company’s stock worth $882,000 after purchasing an additional 23 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Eli Lilly and Company by 4.5% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 52,225 shares of the company’s stock valued at $48,035,000 after buying an additional 2,257 shares in the last quarter. Border to Coast Pensions Partnership Ltd grew its position in shares of Eli Lilly and Company by 59.6% in the 1st quarter. Border to Coast Pensions Partnership Ltd now owns 115,949 shares of the company’s stock worth $106,973,000 after buying an additional 43,286 shares during the period. Pictet Asset Management Holding SA increased its stake in shares of Eli Lilly and Company by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 943,976 shares of the company’s stock worth $867,848,000 after acquiring an additional 63,470 shares in the last quarter. Finally, Yoder Wealth Management Inc. lifted its position in Eli Lilly and Company by 9.1% during the 1st quarter. Yoder Wealth Management Inc. now owns 276 shares of the company’s stock valued at $254,000 after acquiring an additional 23 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,206.51 on Monday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,215.76. The company has a market capitalization of $1.14 trillion, a P/E ratio of 42.86, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53. The firm has a 50 day moving average of $1,036.28 and a 200 day moving average of $1,021.13. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Analysts Set New Price Targets

A number of brokerages have weighed in on LLY. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Barclays boosted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Finally, Jefferies Financial Group boosted their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,235.07.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.